WO2002098453A3 - Orally administering parathyroid hormone and calcitonin - Google Patents

Orally administering parathyroid hormone and calcitonin Download PDF

Info

Publication number
WO2002098453A3
WO2002098453A3 PCT/EP2002/006017 EP0206017W WO02098453A3 WO 2002098453 A3 WO2002098453 A3 WO 2002098453A3 EP 0206017 W EP0206017 W EP 0206017W WO 02098453 A3 WO02098453 A3 WO 02098453A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcitonin
parathyroid hormone
orally administering
pth
administering parathyroid
Prior art date
Application number
PCT/EP2002/006017
Other languages
French (fr)
Other versions
WO2002098453A2 (en
Inventor
Joseph Ault
Moise Azria
Simon David Bateman
James F Mcleod
Original Assignee
Novartis Ag
Novartis Erfingungen Verwaltun
Joseph Ault
Moise Azria
Simon David Bateman
James F Mcleod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002098453(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SK1475-2003A priority Critical patent/SK287697B6/en
Priority to IL15877702A priority patent/IL158777A0/en
Priority to AU2002344371A priority patent/AU2002344371B2/en
Priority to CA2446929A priority patent/CA2446929C/en
Priority to EP02750997A priority patent/EP1397156B1/en
Priority to KR10-2003-7015524A priority patent/KR20040007617A/en
Priority to HU0400120A priority patent/HU229613B1/en
Priority to KR1020127010903A priority patent/KR101320817B1/en
Priority to PL364089A priority patent/PL211976B1/en
Application filed by Novartis Ag, Novartis Erfingungen Verwaltun, Joseph Ault, Moise Azria, Simon David Bateman, James F Mcleod filed Critical Novartis Ag
Priority to MXPA03011027A priority patent/MXPA03011027A/en
Priority to US10/478,631 priority patent/US20040186050A1/en
Priority to JP2003501491A priority patent/JP5073153B2/en
Priority to BRPI0209748A priority patent/BRPI0209748B1/en
Priority to DE60218842T priority patent/DE60218842T2/en
Priority to NZ529439A priority patent/NZ529439A/en
Publication of WO2002098453A2 publication Critical patent/WO2002098453A2/en
Publication of WO2002098453A3 publication Critical patent/WO2002098453A3/en
Priority to IL158777A priority patent/IL158777A/en
Priority to NO20035133A priority patent/NO330093B1/en
Priority to AU2006225157A priority patent/AU2006225157B2/en
Priority to US12/020,700 priority patent/US8153587B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

A method for orally administering a parathyroid hormone, PTH, comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of a calcitonin. The method according to the invention allows for the oral administration of PTH without the hypercalcemia, hypercalcuria and nephrolithiasis side effects.
PCT/EP2002/006017 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin WO2002098453A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MXPA03011027A MXPA03011027A (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin.
US10/478,631 US20040186050A1 (en) 2001-06-01 2002-05-31 Method for orally administering parathyroid hormone (pth)
IL15877702A IL158777A0 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin
CA2446929A CA2446929C (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin
EP02750997A EP1397156B1 (en) 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin
KR10-2003-7015524A KR20040007617A (en) 2001-06-01 2002-05-31 Orally Administering Parathyroid Hormone and Calcitonin
HU0400120A HU229613B1 (en) 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin
KR1020127010903A KR101320817B1 (en) 2001-06-01 2002-05-31 Orally Administering Parathyroid Hormone and Calcitonin
JP2003501491A JP5073153B2 (en) 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin
SK1475-2003A SK287697B6 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin
NZ529439A NZ529439A (en) 2001-06-01 2002-05-31 Method for orally administering parathyroid hormone (PTH)
AU2002344371A AU2002344371B2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin
PL364089A PL211976B1 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin
BRPI0209748A BRPI0209748B1 (en) 2001-06-01 2002-05-31 pharmaceutical composition for oral administration comprising parathyroid hormone (pth), and its use
DE60218842T DE60218842T2 (en) 2001-06-01 2002-05-31 Oral administration of parathyroid hormone and calcitonin
IL158777A IL158777A (en) 2001-06-01 2003-11-06 Pharmaceutical compositions for oral administration comprising parathyroid hormone, a calcitonin and a delivery agent and use thereof in the preparation of medicaments
NO20035133A NO330093B1 (en) 2001-06-01 2003-11-18 Pharmaceutical composition comprising parathyroid hormone and calcitonin and use thereof
AU2006225157A AU2006225157B2 (en) 2001-06-01 2006-09-29 Orally administering parathyroid hormone and calcitonin
US12/020,700 US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
US60/295,169 2001-06-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10478631 A-371-Of-International 2002-05-31
US12/020,700 Continuation US8153587B2 (en) 2001-06-01 2008-01-28 Orally administering parathyroid hormone and calcitonin

Publications (2)

Publication Number Publication Date
WO2002098453A2 WO2002098453A2 (en) 2002-12-12
WO2002098453A3 true WO2002098453A3 (en) 2003-07-31

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Country Status (25)

Country Link
US (2) US20040186050A1 (en)
EP (1) EP1397156B1 (en)
JP (2) JP5073153B2 (en)
KR (3) KR101320817B1 (en)
CN (2) CN101837120A (en)
AT (1) ATE356631T1 (en)
AU (2) AU2002344371B2 (en)
BR (1) BRPI0209748B1 (en)
CA (1) CA2446929C (en)
CO (1) CO5540323A2 (en)
CZ (1) CZ307145B6 (en)
DE (1) DE60218842T2 (en)
EC (1) ECSP034858A (en)
ES (1) ES2282436T3 (en)
HU (1) HU229613B1 (en)
IL (2) IL158777A0 (en)
MX (1) MXPA03011027A (en)
NO (1) NO330093B1 (en)
NZ (1) NZ529439A (en)
PL (1) PL211976B1 (en)
PT (1) PT1397156E (en)
RU (1) RU2300392C2 (en)
SK (1) SK287697B6 (en)
WO (1) WO2002098453A2 (en)
ZA (1) ZA200308625B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837120A (en) 2001-06-01 2010-09-22 诺瓦提斯公司 Method for orally administering parathyroid hormone (PTH)
WO2003015822A1 (en) 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CN101627011A (en) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 The crystalline form of the disodium salt of N-(5-chlorine water poplar acyl group)-8-aminocaprylic acid
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CN101355959B (en) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP2009515993A (en) * 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition
BRPI0817396C8 (en) 2007-11-02 2021-05-25 Emisphere Tech Inc pharmaceutical composition to treat vitamin B deficiência² deficiency
WO2010020978A1 (en) 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
CN104857505A (en) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 Methods And Compositions For Oral Administration Of Proteins
BR112012013725A2 (en) 2009-12-07 2017-01-10 Univ Michigan Tech black bear parathyroid hormone and methods of using the black bear parathyroid hormone.
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (en) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 Traditional Chinese medicine composition for treating blood stasis and lusterless face type hypoparathyroidism
KR101796604B1 (en) * 2016-08-30 2017-11-10 목포대학교 산학협력단 Oral dosage form of parathyroid hormone comprising the gastrointestinal absorption enhancer
KR102115353B1 (en) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Composition comprising chp (cyclo-his pro) and pth for preventing, improving or treating of bone loss related disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000750A1 (en) * 1985-08-01 1987-02-12 The Regents Of The University Of California A method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
WO1998030590A2 (en) * 1997-01-07 1998-07-16 Biomeasure Incorporated Analogs of parathyroid hormone
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
MX9401351A (en) * 1993-02-22 1994-08-31 Alza Corp COMPOSITIONS FOR ORAL SUPPLY FOR ACTIVE AGENTS.
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
ES2297909T3 (en) 1997-02-07 2008-05-01 Emisphere Technologies, Inc. COMPOUNDS AND COMPOSITIONS FOR THE SUPPLY OF ACTIVE AGENTS.
SE9702401D0 (en) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (en) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Syringe for medical purposes comprises a cannula cap which is made of an elastic material and is provided with a well-fitting cavity for the needle carrier
WO2001032201A2 (en) 1999-10-29 2001-05-10 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CN101837120A (en) 2001-06-01 2010-09-22 诺瓦提斯公司 Method for orally administering parathyroid hormone (PTH)
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000750A1 (en) * 1985-08-01 1987-02-12 The Regents Of The University Of California A method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
WO1998030590A2 (en) * 1997-01-07 1998-07-16 Biomeasure Incorporated Analogs of parathyroid hormone
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJITA, TAKUO: "Parathyroid hormone in the treatment of osteoporosis", BIODRUGS (2001), 15(11), 721-728, XP008012814 *
HUNZIKER, J. ET AL: "Mandibular bone formation rates in aged ovariectomized rats treated with anti - resorptive agents alone and in combination with intermittent parathyroid hormone", JOURNAL OF DENTAL RESEARCH (2000), 79(6), 1431-1438, XP008012861 *
WATTS, NELSON B.: "Therapies to improve bone mineral density and reduce the risk of fracture clinical trial results", JOURNAL OF REPRODUCTIVE MEDICINE (2002), 47(1, SUPPL.), 82-92, XP008012813 *

Also Published As

Publication number Publication date
MXPA03011027A (en) 2004-03-19
SK287697B6 (en) 2011-06-06
PT1397156E (en) 2007-05-31
KR20040007617A (en) 2004-01-24
HUP0400120A3 (en) 2012-09-28
EP1397156B1 (en) 2007-03-14
CZ20033232A3 (en) 2004-06-16
US20080119411A1 (en) 2008-05-22
BR0209748A (en) 2004-07-27
JP2005500277A (en) 2005-01-06
ECSP034858A (en) 2004-01-28
JP5073153B2 (en) 2012-11-14
NO330093B1 (en) 2011-02-14
PL211976B1 (en) 2012-07-31
ES2282436T3 (en) 2007-10-16
IL158777A (en) 2012-06-28
KR101320817B1 (en) 2013-10-21
CN1512892A (en) 2004-07-14
ATE356631T1 (en) 2007-04-15
NZ529439A (en) 2005-11-25
RU2003136733A (en) 2005-05-20
CZ307145B6 (en) 2018-02-07
AU2006225157A1 (en) 2006-10-19
HU229613B1 (en) 2014-03-28
CN101837120A (en) 2010-09-22
AU2006225157B2 (en) 2009-04-23
KR20090116836A (en) 2009-11-11
CA2446929C (en) 2013-04-09
DE60218842D1 (en) 2007-04-26
KR20120065429A (en) 2012-06-20
US8153587B2 (en) 2012-04-10
DE60218842T2 (en) 2007-12-20
NO20035133L (en) 2003-11-18
EP1397156A2 (en) 2004-03-17
ZA200308625B (en) 2004-07-13
BRPI0209748B1 (en) 2015-11-24
AU2002344371B2 (en) 2006-06-29
JP2010189423A (en) 2010-09-02
RU2300392C2 (en) 2007-06-10
CO5540323A2 (en) 2005-07-29
NO20035133D0 (en) 2003-11-18
US20040186050A1 (en) 2004-09-23
CA2446929A1 (en) 2002-12-12
HUP0400120A2 (en) 2005-04-28
PL364089A1 (en) 2004-12-13
IL158777A0 (en) 2004-05-12
WO2002098453A2 (en) 2002-12-12
SK14752003A3 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
WO2002098453A3 (en) Orally administering parathyroid hormone and calcitonin
EP1306071A3 (en) A method and dosage form for dispensing a bioactive substance
JP2002523375A5 (en)
MXPA03008072A (en) Oral peptide pharmaceutical dosage form and method of production.
EP1088567A3 (en) Improvements in drug delivery devices
WO1999053910A8 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
IL205262A (en) Use of risedronic acid or pharmaceutically acceptable salt thereof for the manufacture of a medicament for oral administration on one day per month for the prevention or the treatment of osteoporosis
WO2003059270A3 (en) Method for reducing morbidity and mortality in critically ill patients
WO2001082897A3 (en) Liposome drug delivery
EP1291021A3 (en) Pharmaceutical formulations for thyroid hormones
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
CA2453646A1 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
AU6788701A (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
WO2001066102A3 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
CA2385755A1 (en) Prevention of colorectal cancer
MXPA03006157A (en) Hormone replacement therapy method and its administration form.
CA2403674A1 (en) The use of t3 for treating congestive heart failure
WO2002028380A3 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
MD1963F1 (en) Method of treatment of the chronic recurrent aphthous stomatitis
MD1783F1 (en) Method of epilepsy treatment
WO2002055068A3 (en) Cysteine for oral administration for dry eye treatment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200301133

Country of ref document: VN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003/08625

Country of ref document: ZA

Ref document number: 200308625

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 158777

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 529439

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2446929

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002750997

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002344371

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2003-3232

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501216

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 14752003

Country of ref document: SK

Ref document number: 1020037015524

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011027

Country of ref document: MX

Ref document number: 028111613

Country of ref document: CN

Ref document number: 2003501491

Country of ref document: JP

Ref document number: 1886/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 03111065

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2002750997

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10478631

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-3232

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 529439

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529439

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002750997

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097022621

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020127010903

Country of ref document: KR